The Pilot Study of 3-Month Course of Melatonin Treatment in Patients With Nonalcoholic Steatohepatitis

Gonciarz, Maciej; Konturek, Stanisław J.; Bielański, Władysław; Mularczyk, Anna; Brzozowski, Tomasz; Konturek, Peter C.

doi:10.1016/s0016-5085(11)60476-9

Cited by 29 publications

(43 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several studies showed that patients with fatty liver are oxidatively stressed, and the increased intrahepatic levels of fatty acids are a source of this oxidative stress [31,32]. We found that serum PON-1 activity was lower and serum MDA levels were higher in the NAFLD patients than in the patients without NAFLD.…”

Section: Discussionmentioning

confidence: 52%

Fatty Liver Is Associated with Recurrent Bacterial Infections Independent of Metabolic Syndrome

et al. 2011

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 52%

Fatty Liver Is Associated with Recurrent Bacterial Infections Independent of Metabolic Syndrome

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Recently, Gonciarz et al [38] conducted a pilot study of a 3-mo course of melatonin treatment of patients with non-alcoholic steatohepatitis, with encouraging results. Based on our experimental evidence, the case might be made for the use of melatonin in conditions with characteristics of the metabolic syndrome, where excessive free radical generation and oxidative stress may occur.…”

Section: Discussionmentioning

confidence: 99%

“…This view is supported by the findings of a recent study where melatonin improved the metabolic syndrome induced by high doses of fructose in rats, as showed by a decrease in the insulin resistance, together with a decrease in the concentration of serum tumour necrosis factor-a, hepatic lipid peroxide, and hepatic reduced glutathione [39] . Oral administration of melatonin is safe, and without serious acute or chronic toxicity [38,40] . However, its daytime use may cause feelings of sleepiness and fatigue, which can adversely affect performance [41] .…”

Section: Discussionmentioning

confidence: 99%

Melatonin attenuates high fat diet-induced fatty liver disease in rats

Hatzis¹,

Ziakas²,

Kavantzas³

et al. 2013

WJH

View full text Add to dashboard Cite

the statistical analysis and contributed to the interpretation of the data; Kavantzas N did histopathological examinations of the tissue biopsies; Triantafyllou A performed the biochemical tests and the malondialdehyde and glutathione assays; Sigalas P was responsible for the welfare of the animals and the collection and storage of tissues and sera; Andreadou I performed the biochemical tests and the malondialdehyde and glutathione assays; Ioannidis K was responsible for the welfare of the animals and the collection and storage of tissues and sera; Chatzis S was a contributor in writing and revising the manuscript; Filis K was responsible for the welfare of the animals and the collection and storage of tissues and sera; Papalampros A performed invasive procedures on the animals; Sigala F contributed to the conception of the study, performed the invasive procedures, and oversaw the welfare of the animals as well as the collection and storage of tissues and sera. Abstract AIM: To investigate melatonin's preventive action in oxidative stress in a rat model with high fat diet-induced non-alcoholic fatty liver disease (NAFLD). METHODS:NAFLD was induced by high fat diet (HFD) in adult, male, Wistar rats, weighing 180-230 g. After acclimatization for one week, they were randomly assigned to 6 experimental groups that comprised animals on regular diet plus 5 or 10 mg/kg melatonin, for 4 or 8 wk; animals on HFD, with or without 5 or 10 mg/kg melatonin, for 4 or 8 wk; and animals on HFD for 8 or 12 wk, with melatonin 10 mg/kg for the last 4 wk. Liver damage was assessed biochemically by the serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and histologically. Lipid peroxidation and oxidative stress were assessed by malondialdehyde and glutathione levels in liver tissue. Lipidemic indices and portal vein pressure were also measured. RESULTS:Compared to rats not receiving melatonin, rats on 5 or 10 mg/kg of melatonin had lower mean liver weight (-5.0 g and -4.9 g) (P < 0.001) and lower liver weight to body weight ratio (-1.0%) (P < 0.001), for the two doses, respectively. All rats fed HFD without melatonin developed severe, grade Ⅲ, steatosis. Rats on HFD with concurrent use of melatonin showed significantly less steatosis, with grade Ⅲ steatosis observed in 1 of 29 (3.4%) rats on 10 mg/kg melatonin Hatzis G et al . Melatonin and fatty liver and in 3 of 27 (11.1%) rats on 5 mg/kg melatonin. Melatonin was ineffective in reversing established steatosis. Melatonin also had no effect on any of the common lipidemic serum markers, the levels of which did not differ significantly among the rats on HFD, irrespective of the use or not of melatonin. Liver cell necrosis was significantly less in rats on HFD receiving melatonin than in those not on melatonin, with the AST levels declining by a mean of 170 U/L (P = 0.01) and 224 U/L (P = 0.001), and the ALT levels declining by a mean of 62.9 U/L (P = 0.01) and 93.4 U/L (P < 0.001), for the 5 and 10 mg/kg melatonin dose, respectively. Melatonin mitigated l...

show abstract

“…[12] Simple hepatic steatosis with rather good prognosis and nonalcoholic steatohepatitis (NASH) are the spectrum of NAFLD. NASH is often a precursor to the development of cirrhosis and in some cases, hepatocellular carcinoma.…”

Section: Introductionmentioning

confidence: 99%

The Effects of Melatonin in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial

et al. 2017

View full text Add to dashboard Cite

Background:This study was designed to evaluate the effect of melatonin on nonalcoholic fatty liver disease (NAFLD) in compared to placebo.Materials and Methods:A total of 100 patients with histopathological diagnosis NAFLD in two groups of case and control received oral melatonin or placebo thrice daily for 3 months. Collected data were weight, waist, systolic blood pressure (SBP), diastolic blood pressure (DBP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), high sensitive C-reactive protein (hsCRP), fatty liver grade, and side effects which were measured at baseline and after treatment period using standard clinical chemistry techniques.Results:Before treatment the mean of weight, waist, SBP, DBP, ALT, AST, and hsCRP between cases and controls were similar (P > 0.5). After treatment, only the differences in the mean of hsCRP in cases was significantly lower than controls (P = 0.003). In case group, all variables after treatment were significantly decreased compare to baseline (P > 0.5) and only AST after treatment was similar to before treatment (P > 0.5). The mean of a decrease in the level of weight, waist, SBP, and ALT were not statistically significant between groups (P > 0.5). In the case group in compare to control group the level of DBP, AST, and hsCRP significantly more decreased. After treatment fatty, liver grade was statistically improved in more cases than controls (P = 0.001). Side effects were similar between the two groups.Conclusion:Melatonin significantly decreases liver enzymes, so the use of melatonin in patients with NAFLD can be effective.

show abstract

The Pilot Study of 3-Month Course of Melatonin Treatment in Patients With Nonalcoholic Steatohepatitis

Cited by 29 publications

References 0 publications

Fatty Liver Is Associated with Recurrent Bacterial Infections Independent of Metabolic Syndrome

Fatty Liver Is Associated with Recurrent Bacterial Infections Independent of Metabolic Syndrome

Melatonin attenuates high fat diet-induced fatty liver disease in rats

The Effects of Melatonin in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial

Contact Info

Product

Resources

About